Loading...
01/11 03:20
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: declining EBIT margins in key segments, reduced guidance for revenue and EPS, and significant tariff impacts. Despite some positive developments, such as product feedback and market expansion, the overall financial health appears weakened. The Q&A section highlights uncertainties, particularly in China and tariff impacts, with management avoiding clear guidance on EPS growth. The negative adjustments in financial metrics outweigh the positive aspects, leading to a negative sentiment rating.
Revenue $5 billion in the quarter with organic growth of 2% year-over-year. Growth was driven by strength in the U.S. and EMEA regions.
Service Revenue Grew 7% year-over-year, driven by global growth in new and existing customer agreements, including enterprise deals.
Product Revenue Increased by 2% year-over-year.
Organic Orders Growth Up 3% year-over-year, with first half order growth of 7%.
Backlog Record backlog of $21.3 billion, up $2.2 billion year-over-year and $700 million sequentially.
Adjusted EBIT Margin 14.6%, down 80 basis points year-over-year due to tariff impacts, partially offset by lean actions and volume.
Adjusted EPS $1.06 per share, up 6% year-over-year. This included approximately $0.08 of impact from tariffs, with an improved tax rate contributing $0.07 of benefit year-over-year.
Free Cash Flow $7 million, up $189 million year-over-year, primarily due to timing of employee compensation payments.
Adjusted Gross Margin Declined 180 basis points year-over-year, primarily due to tariff expenses and new product investments.
Imaging Segment Organic Revenue Up 1% year-over-year, driven by strong execution in EMEA and the U.S., offset by China headwinds.
Imaging Segment EBIT Margin Declined 110 basis points year-over-year due to tariff pressure, partially offset by productivity improvements.
Advanced Visualization Solutions Organic Revenue Up 2% year-over-year, driven by strong performance in the U.S. as customers invest in AI-enhanced ultrasound solutions.
Advanced Visualization Solutions EBIT Margin Increased 20 basis points year-over-year, driven by productivity and volume.
Patient Care Solutions Organic Revenue Flat year-over-year. Growth in monitoring solutions was offset by life support solutions, which faced a difficult year-over-year comparison due to strong backlog conversion in the prior year.
Patient Care Solutions EBIT Margin Declined 240 basis points year-over-year, primarily driven by inflation and unfavorable portfolio mix, partially offset by productivity actions.
Pharmaceutical Diagnostics Organic Revenue Grew 5% year-over-year, despite a difficult comparison to 14% growth in the prior year.
Pharmaceutical Diagnostics EBIT Margin Declined 200 basis points year-over-year due to planned U.S. radiopharmaceutical investments, Nihon Medi-Physics, and FX headwinds, partially offset by price.
Omni Legend PET/CT systems: Secured the largest order ever in the U.S. for these systems, showcasing strong demand for advanced imaging solutions.
New product introductions: Generated over 50% of sales, highlighting the success of R&D investments and adoption of innovative solutions.
Nuclear medicine solutions: Strong double-digit order growth in diagnostic imaging agents and molecular imaging solutions, including AI-enabled equipment and digital tools.
Flyrcado: Achieved coverage by all 7 Medicare administrative contractors and significant inclusion in commercial insurance policies.
Strategic collaboration with Ascension: Valued up to $90 million in the first year, demonstrating expansion in the U.S. market.
Collaboration in Europe: Secured a $250 million 5-year collaboration, strengthening presence in the European market.
Broadened relationship in Mexico: Expanded long-term partnership with one of the largest providers in Mexico, enhancing market reach.
Revenue growth: Achieved $5 billion in revenue with 2% organic growth, driven by strength in the U.S. and EMEA regions.
Record backlog: Exited the quarter with a record backlog of $21.3 billion, reflecting strong customer demand.
Adjusted EBIT margin: Reported 14.6%, impacted by tariffs but partially offset by productivity and volume improvements.
Free cash flow: Generated $7 million, up $189 million year-over-year, indicating improved cash management.
D3 strategy: Focused on delivering smart devices, drugs, and digital/AI-enabled solutions to address disease states.
Tariff mitigation: Implemented actions to reduce tariff impacts, with a forecasted improvement in adjusted EPS guidance.
Capital allocation: Prioritized organic growth, dividends, share repurchases, and strategic M&A to align with portfolio strategy.
Tariff Impacts: The company faced significant tariff expenses, which negatively impacted adjusted EBIT margin by 80 basis points year-over-year. Tariffs also contributed to a decline in adjusted gross margin by 180 basis points year-over-year. Despite mitigation efforts, tariffs remain a challenge, with a projected $0.45 adjusted EPS impact for 2025.
China Headwinds: Organic revenue growth in the Imaging segment was largely offset by challenges in China, indicating potential market-specific difficulties.
Inflation and Portfolio Mix: The Patient Care Solutions segment experienced a 240 basis point decline in EBIT margin, primarily due to inflation and an unfavorable portfolio mix.
Radiopharmaceutical Investments and FX Headwinds: The Pharmaceutical Diagnostics segment saw a 200 basis point decline in EBIT margin due to planned U.S. radiopharmaceutical investments and foreign exchange headwinds.
Macroeconomic Landscape: The company operates in a mixed macroeconomic environment, which could pose risks to operational and financial performance.
Supply Chain and Inventory Management: The company continues to monitor inventory cycle times and manage working capital strategically, indicating ongoing challenges in supply chain and inventory management.
Organic Revenue Growth: For the full year 2025, the company has raised its organic revenue growth guidance to approximately 3%. For the third quarter of 2025, organic revenue growth is anticipated to be in the range of 2% to 3%.
Adjusted EBIT Margin: The adjusted EBIT margin for the full year 2025 is now forecasted to be in the range of 15.2% to 15.4%, compared to the previous guidance of 14.2% to 14.4%.
Adjusted EPS: The adjusted EPS for the full year 2025 is now expected to be between $4.43 and $4.63, up from the prior estimate of $3.90 to $4.10 per share.
Free Cash Flow: The company now expects to deliver free cash flow of at least $1.4 billion for the full year 2025, an increase from the prior expectation of at least $1.2 billion.
Tariff Impact: The total net tariff impact in the adjusted EPS guidance for 2025 is now $0.45, with mitigation actions expected to reduce this impact further in 2026 and beyond.
Nuclear Medicine Growth: The company expects strong growth in nuclear medicine, particularly in PET imaging, driven by an aging population and novel therapeutics. Investments in nuclear medicine solutions are expected to yield significant patient impact and customer interest.
Higher-Margin Product Launches: Many higher-margin product launches are planned for the second half of 2025 and into 2026, which are expected to drive growth and profitability.
Dividend Maintenance: The company emphasized its commitment to maintaining its dividend as part of its capital allocation strategy.
Share Repurchase Program: In April, the company announced a board-authorized share repurchase program of $1 billion. During the second quarter, approximately $100 million worth of shares were repurchased.
The earnings call reveals strong financial metrics, optimistic guidance, and strategic advancements in nuclear medicine and AI integration, suggesting positive stock movement. Despite some uncertainties in tariff mitigation and competitive impact, raised guidance for revenue, EBIT margin, and EPS, alongside new product launches, supports a positive outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
